Objective: Health maintenance of the general public through vaccination is a significant component of controlling the COVID-19 pandemic. This study aims to examine the perception of Nigerians toward the COVID-19 vaccine. Methods: Informed by the Extended Parallel Process Model (EPPM), 793 Nigerian participants completed a cross-sectional self-administered online survey to assess: (1) their perception of COVID-19 based on fear-mongering information on social media (2) the potential relationship between threat perception, efficacy, and fear associated with the COVID-19 vaccine, vaccine hesitancy, and attitudes toward the decision to uptake the vaccine using structural equation modeling (SEM) analysis, and (3) we further employed the use of the hierarchical regression analysis to test the moderating effect of mindful critical thinking between vaccine hesitancy and attitudes toward vaccines.
Results: Most participants (65.7%) intend to uptake the COVID-19 vaccine. However, many people did not fear the disease (19.2%). Threat perception and efficacy were associated with a decision to uptake the COVID-19 vaccine via the mediation of attitudes toward vaccines. Previous vaccine hesitancy has no relationship with uptake decisions. The hierarchical regression analysis showed that participants exhibiting high critical thinking mindfulness were more interested in taking the vaccine.
Conclusions: The findings of this study demonstrate that EPPM constructs are effective predictors of the public's decision to uptake the COVID-19 vaccine. This research highlights the theoretical and practical implications.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122961 | PMC |
http://dx.doi.org/10.1016/j.hlpt.2023.100749 | DOI Listing |
Pediatr Qual Saf
January 2025
Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Mo.
Introduction: Pediatric coronavirus disease 2019 (COVID-19) vaccination rates in the United States remain lower compared with adults. We aimed to (1) implement a quality improvement initiative to increase COVID-19 vaccination 2-fold in hospitalized patients 12-21 years of age from 4.7% during the baseline period (August 10, 2021-November 1, 2021) to 9.
View Article and Find Full Text PDFPLOS Glob Public Health
January 2025
Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
J Racial Ethn Health Disparities
January 2025
Adam Smith Business, School University of Glasgow, 2 Discovery Place, G11 6EY, Glasgow, Scotland.
This study highlights how the intersection of multiple factors shapes the experiences of Scotland's Black, African, and Caribbean communities in their access and uptake of COVID-19 vaccines in the vaccination programme's first, second, and booster stages. There was particular interest in understanding the vaccination journey, from scheduling an appointment to attending the appointment. Data in this study was collected between the 1 and 30 April 2022 using a triangulated approach, including a survey (with 408 responses), interviews (26), and focus group discussions (5 groups involving 30 participants).
View Article and Find Full Text PDFPLoS One
December 2024
Escuela de Salud Pública, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background: Most of the evidence on risk factors for COVID-19 complications comes from North America or Europe with very little research from Latin-America. We aimed to evaluate the association between sociodemographic, clinical factors and the risk of COVID-19 complications among adults in Chile, the fifth Latin-American country with more COVID-19 reported cases since de beginning of the Pandemic.
Methods: A retrospective population-based cohort study using data from electronic health records from a large Primary Care Network, linked to national hospital, immunization, Covid-19 PCR surveillance, mortality and birth records.
Pediatr Infect Dis J
November 2024
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD.
Background: Following maternal COVID-19 vaccination, the persistence of antibodies in sera and breast milk for mothers and infants is not well characterized. We sought to describe the persistence of antibodies through 2 months after delivery in maternal and infant serum and breast milk following maternal COVID-19 mRNA vaccination and to examine differences by receipt of booster dose during pregnancy or postpartum.
Methods: This is a prospective cohort study with enrollment from July 2021 to January 2022 at 9 US academic sites.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!